Stage IV Skin Melanoma Clinical Trial
Official title:
A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
This phase I/II trial studies the side effects and how well pembrolizumab and imatinib mesylate work in treating patients with melanoma with c-KIT mutation or amplification that has spread to nearby tissue or other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and imatinib mesylate may work better in treating patients with melanoma with c-KIT mutation or amplification that has spread to nearby tissue or other places in the body.
PRIMARY OBJECTIVES:
I. To assess the best overall response rate (BORR = complete response + partial response) of
the combination of pembrolizumab and imatinib for treatment of melanomas harboring c-Kit
mutation or amplification.
II. To evaluate the safety and adverse effect profile of the combination of pembrolizumab and
imatinib in patients with melanomas harboring c-KIT aberrations (mutations or
amplifications).
SECONDARY OBJECTIVES:
I. To assess the median time to progression (TTP), progression free survival (PFS), and
overall survival (OS).
TERTIARY OBJECTIVES:
I. Assessment of programmed cell death ligand (PD-L)1 expression in melanoma patients with
c-KIT aberrations before and after combined therapy.
OUTLINE:
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and imatinib
mesylate orally (PO) once daily (QD) on days 1-21. Courses repeat every 3 weeks in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and every 9 weeks
for 1 year, and then every 12 weeks thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
| Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
| Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
| Completed |
NCT00026221 -
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02876068 -
Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00397982 -
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
|
Phase 2 | |
| Terminated |
NCT01744171 -
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
|
Phase 1 | |
| Terminated |
NCT02748564 -
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
| Completed |
NCT02941744 -
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
|
Phase 1/Phase 2 | |
| Completed |
NCT01789827 -
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
|
Early Phase 1 | |
| Terminated |
NCT01970527 -
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02654821 -
Study With T-cel Receptor Gene Therapy in Metastatic Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Completed |
NCT00866177 -
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03719131 -
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
|
Phase 2 | |
| Completed |
NCT02716948 -
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
|
Phase 1 | |
| Completed |
NCT00110019 -
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 3 |